Image IQ Quiz: Patient Presents with Shortness of Breath and Distress

Catch up on a variety of FDA news in radiology from the past week.

Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.

In a study involving over 700 participants who had chest CT and brain MRI, those with diabetes and lower vertebral bone mineral density (vBMD) had a nearly five percent faster total accumulation of white matter hyperintensity (WMH) in comparison to those without diabetes.

Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.

Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.

In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.

Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?

Catch up on the top radiology content of the past week.